Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
11 evidence topics · 8 sources
RAPIDe-3 subgroups: participants with at least one study drug-treated attack
RAPIDe-3 subgroups: hereditary angioedema with normal C1 inhibitor
RAPIDe-3 regional subgroups: North America and Europe/Rest of World, all participants with treated attacks
RAPIDe-3 regional subgroups: median times to onset of symptom relief, reduction in attack severity, and complete resolution
| Outcome and region | Deucrictibant IR | Placebo |
|---|---|---|
| Onset of symptom relief, North America | “1.20 hours (95% CI: 0.84, 1.84)” | “6.55 hours (95% CI: 1.88, >12)” |
| Onset of symptom relief, Europe/Rest of World | “1.28 hours (95% CI: 1.04, 1.41)” | “>12 hours (95% CI: 5.74, >12)” |
| Reduction in attack severity, North America | “2.43 hours (95% CI: 1.03, 5.12)” | “>12 hours (95% CI: 2.65, >12)” |
| Reduction in attack severity, Europe/Rest of World | “2.53 hours (95% CI: 1.70, 2.98)” | “>12 hours (95% CI: 12.10, >12)” |
| Complete symptom resolution, North America | “11.61 hours (95% CI: 2.94, 26.14)” | “>48 hours (95% CI: 17.21, >48)” |
| Complete symptom resolution, Europe/Rest of World | “12.04 hours (95% CI: 8.64, 21.79)” | “>48 hours (95% CI: >48, >48)” |
RAPIDe-1 attack location: cutaneous and abdominal attacks
Sebetralstat pooled phase 2 and 3 trials: subgroups by location, severity, age, sex, region, and regimen
“In the subgroup analysis, results favoring sebetralstat versus placebo were generally consistent when analyzed by pooled primary HAE attack location (mucosal, abdominal only, or subcutaneous), baseline attack severity, age, sex, geographic region, and treatment regimen (Fig. 3). Of note, HAE attacks with a baseline severity of “Severe” or “Very Severe” more strongly favored sebetralstat over placebo in terms of time to beginning of symptom relief compared with attacks with a baseline severity of “Mild” or “Moderate”, although results should be interpreted with caution due to the wide confidence intervals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For HAE attacks rated “Severe” or “Very Severe” at baseline, conventional medication was used for 2 of 14 attacks (14.3%) treated with sebetralstat 300 mg, 3 of 20 attacks (15.0%) treated with sebetralstat 600 mg, and 6 of 14 attacks (42.9%) treated with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analyses are exploratory in nature and not adjusted for multiplicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sebetralstat open-label extension: attacks during long-term prophylaxis by severity, location, and age
“In subgroup analyses by attack severity at the time of sebetralstat administration, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 1.8 (1.0-7.0) hours, 1.3 (0.8-3.5) hours, and 1.3 (0.5-1.8) hours for mild, moderate, and severe/very severe attacks, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analyses by attack location showed median (IQR) times to beginning of symptom relief in participants receiving any LTP agent of 1.3 (0.7-2.2) hours, 1.4 (0.9-4.1) hours, 1.0 (0.5-2.2), and 1.7 (1.2-6.0) hours for attacks with mucosal involvement, attacks with laryngeal involvement, attacks limited to the abdomen, and attacks limited to subcutaneous tissues, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In subgroup analyses by age, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 0.7 (0.3-1.4) hours and 1.7 (1.1-5.5) hours for participants aged <18 years (n = 5) and participants aged ≥18 years (n = 30), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the study was not designed or powered to evaluate differences in the effectiveness of sebetralstat by the specific LTP agent received or differences between subgroups; these data are reported to offer a preliminary clinical overview.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Icatibant: time to treatment, attack location, and severity in the Icatibant Outcome Survey
“Attack duration was significantly shorter in patients treated <1 hour of attack onset compared with those treated ≥1 hour (6.1 hours versus 16.8 hours [p<0.001]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Self-administrators were more likely to treat early and experience shorter attacks than those treated by a healthcare professional.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both abdominal and cutaneous attacks were found to be of shorter total duration when treated early. Additionally, early treatment resulted in significant reductions in attack duration regardless of attack severity (Tables 4 and 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide: response by time to treatment in the EDEMA trials
“Change from baseline in MSCS score and TOS at 4 hours revealed significantly better response to ecallantide versus placebo for patients treated >2-4 (n = 46; p = 0.002; p = 0.003) or >4-6 (n = 47; p = 0.044; p = 0.043) hours after symptom onset. Fewer patients were treated within 2 hours of symptom onset; for these patients (n = 10; p = 0.752; p = 0.422) treatment did not achieve statistical significance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Icatibant and plasma-derived C1 inhibitor: attack site and time to treatment in a prospective cohort
“Attack severity and attack site were not found to be associated with different remission rates, with the only exception for laryngeal attacks (HR 1.44, 95% CI 1.07 to 1.95).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, shorter time to treatment was associated with a small (2%) but significant positive effect on remission rates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote